Esperion Reveals Pricing for Public Common Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Source: Globenewswire
Public Offering Announcement: Esperion Therapeutics has priced a public offering of 30 million shares of common stock at $2.50 per share, with expected gross proceeds of approximately $75 million, set to close around October 9, 2025.
Company Overview: Esperion focuses on developing oral, non-statin medications for patients with elevated LDL cholesterol and is advancing its pipeline, including next-generation ATP citrate lyase inhibitors, supported by a significant clinical trial.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
